As Phacilitate prepares to launch their Investment in Advanced Therapies Summit (London, 3rd May) in partnership with Biotech and Money, they caught up with Bill Podd (Landmark Capital) on what are the challenges in early stage investment for the biotech industry.
At their bioleaders event in January, they had the chance to catch up with William Podd, Founder, President and CEO of Landmark Capital, to ask him why there is so much enthusiasm amongst investors for the advanced therapeutics field, whilst giving them the unique perspective of what investors look for in the technologies they buy into.
William also explains his views on how and where biotech companies can actively seek investment themselves, and how philanthropies and foundations sometimes focus their investment on one specific disease, looking at a range of companies in that particular area.
Finally, William explains what investors can do to understand where to invest in the advanced therapeutics field, especially if it's not necessarily their background, and how social impact can have a big effect.
Want to gain more insights just like this?
Register for the Investment for Advanced Therapies Summit now to gain more insights just like this, from all of the major players in the space, including, biotechs, pharma and investors. And with investors already invited to attend the event for free, there really will be something for everyone at the event!
Add Your Response